We are talking here about a 50bagger potential.
What would justify such a gigantic performance?
VorEloxin, a first class DNA agent for treatment of acute myeloid leukemia, showed unique efficacy with 31% remission and great tolerability - so great, that elderly AML patients, who could not be treated with chemotherapy could have soon a treatment option. Sunesis estimates $1 bln market opporunity for treatment of AML.
VorEloxin is also in phase for treatment of ovarian cancer. Results are expecte to be released in April 2010. Sunesis estimates the market potential for treatment ovarian cancer to be up to $2.5 bln.
Further, Sunesis intends to extend VorEloxin for treatment of ohter cancer indications.
From Sunesis homepage:
"Voreloxin has demonstrated objective tumor responses in a variety of tumor types has been generally well tolerated. Clinical responses with single agent voreloxin have been seen in these indications, as well as in non-small cell and small cell lung cancers. In addition, complete remissions have been observed in AML patients treated with voreloxin in combination with cytarabine."